Leading Companies Consolidate Their Roles in the Precision Psychiatry Market

The precision psychiatry sector is gaining considerable attention as advancements in technology and personalized medicine continue to transform mental health care. Positioned to revolutionize psychiatric treatment, this market is on track for significant expansion, driven by innovative tools and collaborative efforts across the healthcare landscape. Here's a detailed look at its growth prospects, major players, emerging trends, and market segmentation.

Projected Market Size and Growth of the Precision Psychiatry Market
The precision psychiatry market is anticipated to grow rapidly, reaching a value of $8.58 billion by 2029. This expansion represents a compound annual growth rate (CAGR) of 14.5%. Several factors contribute to this growth, such as the increased use of wearable biosensors, stronger partnerships between biotech firms and healthcare providers, growth in telepsychiatry services, more funding directed toward startups focused on precision psychiatry, and wider adoption of genetic testing in mental health evaluations. Key trends expected to influence the market include digital therapeutic innovations, advances in neuroimaging and biomarker research, ongoing investments in personalized psychiatric treatment development, improvements in cognitive assessment technologies, and breakthroughs in remote monitoring systems.

Download a free sample of the precision psychiatry market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=30359&type=smp

Emerging Companies Making an Impact in Precision Psychiatry
The precision psychiatry market features several notable companies shaping its future, including Johnson & Johnson, F. Hoffmann-La Roche Ltd, Pfizer Inc., AbbVie Inc., AstraZeneca plc, Novartis AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Eli Lilly and Company, Otsuka Pharmaceutical Company Limited, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Illumina Inc., ARUP Laboratories Inc., Sumitomo Dainippon Pharma Company Limited, QIAGEN N.V., Neurocrine Biosciences Inc., Tempus Labs Inc., Myriad Genetics Inc., MedGenome Labs Ltd., Genomind Inc., and STALICLA SA.

Notably, in January 2025, Johnson & Johnson, headquartered in the US, acquired Intra-Cellular Therapies Inc. for about $14.6 billion. This strategic acquisition aims to broaden Johnson & Johnson's portfolio of innovative psychiatric drugs while leveraging Intra-Cellular Therapies' expertise in mechanism-based drug development for central nervous system disorders. Intra-Cellular Therapies is a US company focused on developing targeted neuropsychiatric treatments that align closely with the goals of precision psychiatry.

View the full precision psychiatry market report:
https://www.thebusinessresearchcompany.com/report/global-precision-psychiatry-market-report

Emerging Trends Shaping the Precision Psychiatry Field
Leading companies within the precision psychiatry space are concentrating on developing new therapies, including prescription digital therapeutics, which offer personalized and data-driven treatment options for psychiatric conditions. Prescription digital therapeutics are clinician-prescribed software interventions delivering evidence-based behavioral therapy modules through mobile devices to support symptom improvement and treatment adherence.

For example, in August 2024, Otsuka Precision Health Inc., a US subsidiary specializing in precision health, partnered with Click Therapeutics Inc., a digital therapeutics company, to launch Rejoyn. This product is the first prescription digital therapeutic cleared by the FDA for adjunctive treatment of major depressive disorder (MDD) symptoms. Rejoyn provides a six-week cognitive-emotional training program that combines emotional faces memory tasks with cognitive behavioral therapy (CBT) modules. It also supports digital prescribing, patient engagement, and remote monitoring. The introduction of Rejoyn marks a major advancement in precision psychiatry, illustrating how digital therapeutics can complement medication to deliver more individualized care. It also sets the stage for greater adoption of software-based treatments that use real-time patient data to enhance treatment effectiveness and adherence.

Breakdown of Market Segments in Precision Psychiatry
The precision psychiatry market is segmented in several ways to comprehensively cover this evolving field:
1) Therapeutic Approaches: Pharmacotherapy, Psychotherapy, Neurostimulation, Digital Therapeutics, Combination Therapies
2) Technologies: Genetic Testing, Biomarker Analysis, Brain Imaging Techniques, Wearable Devices, Artificial Intelligence and Machine Learning Solutions
3) Disorders Addressed: Depression, Anxiety Disorders, Bipolar Disorder, Schizophrenia, Post-Traumatic Stress Disorder (PTSD)
4) Applications: Diagnosis, Treatment, Research
5) End Users: Clinics, Hospitals, Research Institutes, Pharmaceutical Companies, Home Care Settings

Further detailed subsegments include:
- Pharmacotherapy: Antidepressants, Antipsychotics, Mood Stabilizers, Anxiolytics, Stimulants
- Psychotherapy: Cognitive Behavioral Therapy, Interpersonal Therapy, Psychodynamic Therapy, Dialectical Behavior Therapy, Mindfulness-Based Therapy
- Neurostimulation: Transcranial Magnetic Stimulation, Electroconvulsive Therapy, Vagus Nerve Stimulation, Deep Brain Stimulation, Transcranial Direct Current Stimulation
- Digital Therapeutics: Mobile App-Based Therapy, Virtual Reality Therapy, Web-Based CBT Programs, Remote Patient Monitoring Tools, AI-Guided Interventions
- Combination Therapies: Various pairings of pharmacotherapy, psychotherapy, neurostimulation, and digital therapeutics, as well as multimodal precision treatment programs.

This comprehensive segmentation highlights the diverse approaches being employed to tailor psychiatric care through precision medicine, reflecting a strong future growth trajectory for the market.

With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.